JNJ

167.96

-0.69%↓

NVS

116.53

-0.95%↓

MDT

92.36

+0.51%↑

ELV.US

291.23

+0.34%↑

VEEV

288.67

-0.36%↓

JNJ

167.96

-0.69%↓

NVS

116.53

-0.95%↓

MDT

92.36

+0.51%↑

ELV.US

291.23

+0.34%↑

VEEV

288.67

-0.36%↓

JNJ

167.96

-0.69%↓

NVS

116.53

-0.95%↓

MDT

92.36

+0.51%↑

ELV.US

291.23

+0.34%↑

VEEV

288.67

-0.36%↓

JNJ

167.96

-0.69%↓

NVS

116.53

-0.95%↓

MDT

92.36

+0.51%↑

ELV.US

291.23

+0.34%↑

VEEV

288.67

-0.36%↓

JNJ

167.96

-0.69%↓

NVS

116.53

-0.95%↓

MDT

92.36

+0.51%↑

ELV.US

291.23

+0.34%↑

VEEV

288.67

-0.36%↓

Search

Abbott Laboratories

Open

SectorGezondheidszorg

125.92 0.41

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

125

Max

126.43

Belangrijke statistieken

By Trading Economics

Inkomsten

-7.9B

1.3B

Verkoop

784M

11B

K/W

Sectorgemiddelde

15.631

38.156

EPS

1.26

Dividendrendement

1.88

Winstmarge

12.792

Werknemers

114,000

EBITDA

-465M

2.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+15.37% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.88%

2.50%

Volgende Winsten

15 okt 2025

Volgende dividenddatum

15 aug 2025

Volgende Ex Dividend datum

14 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-13B

216B

Vorige openingsprijs

125.51

Vorige sluitingsprijs

125.92

Nieuwssentiment

By Acuity

33%

67%

93 / 375 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Abbott Laboratories Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 jul 2025, 12:10 UTC

Winsten

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

16 apr 2025, 16:21 UTC

Winsten

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16 apr 2025, 12:14 UTC

Winsten

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

17 jul 2025, 13:14 UTC

Winsten

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 jul 2025, 12:16 UTC

Winsten

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 jul 2025, 11:32 UTC

Winsten

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17 jul 2025, 11:32 UTC

Winsten

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17 jul 2025, 11:31 UTC

Winsten

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Sales $11.14B >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Net $1.78B >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Adj EPS $1.26 >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q EPS $1.01 >ABT

17 jul 2025, 09:08 UTC

Populaire aandelen

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

1 jul 2025, 18:41 UTC

Acquisities, Fusies, Overnames

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

16 apr 2025, 15:09 UTC

Marktinformatie

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16 apr 2025, 14:17 UTC

Winsten

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16 apr 2025, 11:34 UTC

Winsten

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16 apr 2025, 11:33 UTC

Winsten

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16 apr 2025, 11:32 UTC

Winsten

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16 apr 2025, 11:32 UTC

Winsten

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16 apr 2025, 11:31 UTC

Winsten

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16 apr 2025, 11:30 UTC

Winsten

Abbott Reaffirms Full-Yr Guidance

16 apr 2025, 11:30 UTC

Winsten

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16 apr 2025, 11:30 UTC

Winsten

Abbott Labs 1Q Sales $10.36B >ABT

16 apr 2025, 11:30 UTC

Winsten

Abbott Labs 1Q Net $1.33B >ABT

Peer Vergelijking

Prijswijziging

Abbott Laboratories Prognose

Koersdoel

By TipRanks

15.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 145.17 USD  15.37%

Hoogste 159 USD

Laagste 135 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Abbott Laboratories - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

16

Buy

3

Hold

0

Sell

Technische score

By Trading Central

132.82 / 134.43Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

93 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.